Research
St. John's Wort
162 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis assessed the efficacy of pharmacological interventions, including supplements, for mild depression. St. John's Wort was compared to fluoxetine in two trials, showing no significant difference in response or dropout rates. Eicosapentaenoic acid and Rhodiola rosea showed significant improvements in depressive symptoms compared to placebo, while magnesium chloride was effective in non-blinded trials.
The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials.
Meta-analysis of 14 clinical trials with 2270 depression patients comparing St. John's Wort to SSRIs and placebo. St. John's Wort reduced depressive symptoms and HAMD scores with fewer risks and side effects than SSRIs.
Triggers for acute mood episodes in bipolar disorder: A systematic review.
Systematic review identifying triggers of acute mood episodes in bipolar disorder. St. John's Wort and other factors like antidepressants and energy drinks were identified as triggers for manic/hypomanic episodes.
Efficacy and safety of three plant extracts based formulations of vagitories in the treatment of vaginitis: a randomized controlled trial.
RCT of 210 women with vaginitis testing three herbal vagitory formulations based on extracts of St. John's wort, chamomile, calendula, yarrow, shepherd's purse, and tea tree oil. Tea tree oil-based vagitories showed better efficiency, while St. John's wort and five herbs-based vagitories were better tolerated in postmenopausal women. All formulations had a positive effect on vaginitis symptoms.
Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
Meta-analysis of 27 clinical trials with 3808 patients comparing St John's wort to SSRIs for depression. St John's wort showed comparable response and remission rates, and significantly lower discontinuation rates compared to SSRIs, supporting its efficacy in ameliorating depressive symptoms.
A systematic review of St. John’s wort for major depressive disorder
This systematic review evaluated the efficacy and safety of St. John's Wort (SJW) for treating Major Depressive Disorder (MDD) in adults. SJW was found to be more effective than placebo in improving depression symptoms and had fewer adverse events compared to antidepressants, with no significant difference in treatment effectiveness for mild and moderate depression.
A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults
Meta-analysis comparing the efficacy and safety of St John's wort extract to SSRIs in treating depression. St John's wort extract showed similar efficacy to SSRIs in clinical response and remission but had a significantly lower rate of adverse events, indicating superior safety.
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.
Reanalysis of data from four controlled clinical trials comparing the tolerability of St. John's wort extract WS 5570 to paroxetine and other SSRIs in 1661 outpatients with major depression. WS 5570 showed a comparable adverse event rate to placebo and significantly lower rates than paroxetine, with fewer side effects such as sedation and sexual dysfunction.
St John's wort for major depression.
Systematic review of 29 trials with 5489 patients comparing St. John's wort to placebo and standard antidepressants for major depression. St. John's wort was found to be superior to placebo and similarly effective as standard antidepressants, with fewer side effects.
Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials.
Re-analysis of data from two double-blind, randomized, placebo-controlled clinical trials and a long-term study on St. John's wort extract WS 5570 for mild depression. Patients treated with WS 5570 showed significant decreases in HAMD scores compared to placebo, with higher rates of response and remission.
[Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort].
Meta-analysis of 30 studies comparing St. John's Wort to placebo and synthetic antidepressants for mild to moderate depression. St. John's Wort showed significant advantage over placebo and similar effectiveness to synthetic antidepressants, with better results in mild to moderate depression and a favorable side-effect profile.
St John's wort for depression.
Systematic review of 27 trials with 2291 patients comparing St. John's wort to placebo and standard antidepressants for depressive disorders. St. John's wort was significantly superior to placebo and similarly effective as standard antidepressants, with fewer side effects reported.
St John's wort for depression--an overview and meta-analysis of randomised clinical trials.
Systematic review and meta-analysis of 23 randomised trials with 1757 outpatients with mild or moderately severe depressive disorders. Hypericum extracts were significantly superior to placebo and similarly effective as standard antidepressants, with fewer side effects.
The Effect of St. John's Wort Oil (Hypericum Perforatum L.) in Knee Osteoarthritis: A Randomized Controlled and Qualitative Study.
This study investigated the effect of St. John's Wort oil on pain intensity and physical functions in people with knee osteoarthritis. A single-blind, randomized, placebo-controlled trial with 60 patients showed that the experimental group treated with St. John's Wort oil had significantly lower pain and improved physical function compared to the placebo group.
Effect of St. John's wort oil and olive oil on the postoperative complications after third molar surgery: randomized, double-blind clinical trial.
This randomized, double-blind clinical trial evaluated the effects of St. John's wort oil and virgin olive oil on postoperative complications after third molar surgery, comparing them to chlorhexidine gluconate plus benzydamine hydrochloride mouthwash. No significant differences were found between the groups regarding pain, swelling, jaw function, or periodontal healing.
Warfarin and food, herbal or dietary supplement interactions: A systematic review.
Systematic review of 149 articles describing interactions between 78 herbs, food, or dietary supplements and warfarin. The review found that 57.7% of these substances potentiate warfarin effects, 29.5% inhibit, and 12.8% have limited impact. Some herbs and supplements, including St. John's Wort, are associated with increased bleeding risks.
Interaction of herbal products with prescribed medications: A systematic review and meta-analysis.
Systematic review and meta-analysis of herb-drug interactions, focusing on St. John's Wort, Echinacea purpurea, and Green Tea. St. John's Wort decreased the AUC and clearance of midazolam, while Echinacea purpurea increased its clearance. Green Tea significantly decreased plasma concentration of nadolol. The study highlights the importance of understanding herb-drug interactions in medication plans.
The safety of St John's wort (Hypericum perforatum) in pregnancy and lactation: A systematic review of rodent studies.
Systematic review of 10 rodent studies assessing the safety of St John's wort during the perinatal period. The review found significant methodological limitations in the studies, including lack of botanical verification and inadequate dosage rationale, rendering the results unreliable.
The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
Bayesian meta-analysis of 109 publications on CYP3A4 and Pgp substrate interactions with grapefruit juice and St. John's Wort. The study quantified inhibition and induction effects on pharmacokinetics, providing predictions for interaction magnitudes and refining uncertainty factors for chemical risk assessment.
A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin.
Systematic review of pharmacokinetic and pharmacodynamic interactions between herbal medicines and warfarin. St John's wort and echinacea affected the PK parameters of warfarin, while ginseng, ginger, garlic, and cranberry had no significant effect. American ginseng altered the PD parameters of warfarin. Conflicting results were found for ginkgo and cranberry. The quality of evidence was low, and no major adverse events were reported.
The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.
Systematic review assessing the influence of CYP450 inducers on the pharmacokinetics of voriconazole. St John's Wort significantly decreased the mean AUC of voriconazole, indicating a potential drug-supplement interaction. The review highlights the need for TDM and dose adjustment when voriconazole is co-administered with certain inducers.
Comparative Benefits and Harms of Complementary and Alternative Medicine Therapies for Initial Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.
Systematic review and meta-analysis comparing the benefits and harms of CAM therapies, including acupuncture, omega-3 fatty acids, S-adenosyl methionine, and St. John's wort, with second-generation antidepressants for major depressive disorder. Found little difference in efficacy but noted higher treatment discontinuation due to adverse events for SSRIs compared to St. John's wort. Evidence quality was low or insufficient.
St. John's Wort for Major Depressive Disorder: A Systematic Review.
Systematic review of 35 RCTs evaluating St. John's Wort for major depressive disorder. Moderate evidence suggests SJW improves depression symptoms compared to placebo and is comparable to antidepressants. Adverse events were similar to placebo and fewer than with antidepressants, but confidence in this conclusion is limited.
Co-administration of St. John's wort and hormonal contraceptives: a systematic review.
Systematic review examining the interaction between St. John's wort and hormonal contraceptives. Evidence suggests increased risk of ovulation and breakthrough bleeding, indicating decreased contraceptive efficacy when co-administered with SJW. Pharmacokinetic evidence is mixed but suggests weak to moderate induction of COCs metabolism.
St John’s wort use in Australian general practice patients with depressive symptoms: their characteristics and use of other health services
Secondary analysis of data from an Australian cohort study on depression, examining St John's Wort (SJW) use. SJW users were more likely to be depressed and use both conventional and complementary health services. No significant differences in satisfaction or trust in general practitioners were found between SJW users and non-users.
Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews.
Cochrane systematic review update on tobacco addiction interventions, including evidence that St John's Wort does not have a significant effect on long-term smoking cessation. The review also covers other interventions like varenicline, bupropion, and behavioral support.
Drug-drug interactions between warfarin and psychotropics: updated review of the literature.
Systematic review of literature documenting interactions between warfarin and psychotropics, focusing on cytochrome P450 system and protein binding. St. John's Wort is noted to significantly decrease INR when used with warfarin, highlighting important drug-supplement interactions.
A systematic review and meta-analysis on the use of Hypericum perforatum (St. John's Wort) for pain conditions in dental practice.
Systematic review and meta-analysis on the use of Hypericum perforatum (St. John's Wort) for pain conditions in dental practice. The review found high heterogeneity in pain effects and an overall effect favoring Hypericum, but not statistically significant. The studies included also used Arnica montana, influencing results.
Depression in children and adolescents.
Systematic review evaluating the effectiveness and safety of various interventions for depression in children and adolescents, including pharmacological, psychological, and complementary treatments. St John's Wort (Hypericum perforatum) is among the interventions reviewed.
St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.
An 8-week double-blind, placebo-controlled, randomized trial of 600 mg St. John's wort extract LI160 vs. placebo in 200 patients with atypical depression. The study found significant improvements in depression scores for LI160, particularly in moderately depressed patients, supporting its beneficial effect in atypical depression.
Depression in children and adolescents.
Systematic review evaluating the effectiveness and safety of various interventions for depression in children and adolescents, including pharmacological, psychological, and complementary treatments. St John's Wort (Hypericum perforatum) is among the substances reviewed.
Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Systematic review of interactions between herbal medicines and prescribed drugs. St John's wort, ginkgo, ginseng, garlic, echinacea, saw palmetto, and kava were reviewed. St John's wort notably reduces plasma concentrations of various drugs via cytochrome P450 and P-glycoprotein induction, with potential serious clinical consequences.
Kava and St. John's Wort: current evidence for use in mood and anxiety disorders.
Systematic review of kava and St. John's Wort for mood and anxiety disorders. Evidence supports St. John's Wort for mild-moderate depression and kava for generalized anxiety. Weak evidence for St. John's Wort in seasonal affective disorder. No human trials for kava in other affective disorders.
Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis.
Meta-analysis comparing the efficacy and tolerability of Hypericum perforatum (St. John's Wort) with selective serotonin reuptake inhibitors (SSRIs) in managing major depressive disorder. The analysis found no significant differences in efficacy or adverse events between Hypericum and SSRIs, but Hypericum had a lower withdrawal rate due to adverse events.
An update on clinical drug interactions with the herbal antidepressant St. John's wort.
Systematic review of clinical drug interactions with St. John's Wort (SJW), highlighting its ability to alter pharmacokinetics and clinical response of various drugs. SJW is a potent inducer of CYP3A4 and P-gp, leading to decreased drug concentrations and potential adverse reactions when combined with certain medications.
Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].
This randomized, double-blind, placebo-controlled, multi-center trial assessed the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS 5570 at doses of 600 mg/day and 1200 mg/day in patients with mild to moderate major depression. Both doses were found to be more effective than placebo in reducing depression scores, with a higher remission rate in the 1200 mg/day group. The incidence of adverse events was low and consistent with known profiles.
The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.
Systematic review of clinical trials assessing the effect of St John's wort extracts on CYP3A metabolism. High-dose hyperforin extracts were found to induce CYP3A, while low-dose extracts showed no significant effect.
St. John's wort and the treatment of mild to moderate depression: a systematic review.
Systematic review of randomized controlled trials assessing the efficacy of St. John's Wort in treating mild to moderate depression. All studies showed significant improvements in depression scores for those taking St. John's Wort compared to placebo or pharmaceutical antidepressants.
St John's wort for depression.
Meta-analysis of 37 trials comparing St. John's wort extracts to placebo and standard antidepressants in treating depressive disorders. Results showed mixed effectiveness, with some trials indicating minimal benefits and others showing similar effects to standard antidepressants. Adverse effects were less frequent with St. John's wort compared to older antidepressants.
St John's wort for depression: meta-analysis of randomised controlled trials.
Systematic review and meta-analysis of 37 double-blind RCTs comparing Hypericum extracts with placebo or standard antidepressants in adults with depressive disorders. Larger trials showed minor effects over placebo in major depression, while smaller trials showed marked effects. Hypericum had similar effects to standard antidepressants.
Adverse effects of St. John's Wort: a systematic review.
Systematic review of clinical evidence on the safety and tolerability of hypericum extracts. Data from 35 double-blind randomized trials showed similar dropout and adverse effects rates to placebo, lower than older antidepressants, and slightly lower than SSRIs. Observational studies with 35,562 patients reported dropout rates due to adverse effects ranging from 0% to 5.7%. Interactions with drugs, particularly cyclosporine, were noted as relevant adverse effects.
How effective is St John's wort? The evidence revisited.
Meta-analysis reevaluating the effectiveness of St. John's wort as an antidepressant. Recent studies show smaller effect sizes compared to earlier studies, with a reduced risk ratio in the updated analysis. Publication bias and small-study effects were assessed, suggesting St. John's wort may be less effective than previously assumed.
Interaction of St John's wort with conventional drugs: systematic review of clinical trials.
Systematic review of 22 pharmacokinetic trials examining the interaction of St John's wort with conventional drugs. Most trials found a decrease in the systemic bioavailability of conventional drugs when taken with St John's wort, indicating potential drug-supplement interactions.
St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist.
Systematic review of St. John's wort, focusing on its adverse effects and drug interactions. The review discusses its effectiveness compared to placebo and tricyclic antidepressants for mild-to-moderate depression, and highlights significant drug interactions.
Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.
Double-blind, randomized, placebo-controlled trial with 375 patients investigating the antidepressant efficacy and safety of 300 mg t.i.d. of Hypericum perforatum extract WS 5570. WS 5570 produced a significantly greater reduction in Hamilton depression scale scores compared to placebo, with more patients achieving treatment response or remission. It was effective in reducing depression-related core symptoms and had comparable adverse events to placebo.
Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial.
Double-blind, randomized, placebo-controlled trial of 340 adult outpatients with major depression testing the efficacy and safety of Hypericum perforatum (St John's wort) compared to placebo and sertraline. The study found no significant difference in efficacy between H perforatum and placebo in improving depression scores, suggesting no effect of H perforatum in moderately severe major depression.
St John's Wort supplements endanger the success of organ transplantation.
Systematic review of interactions between St John's Wort and cyclosporine, identifying 11 case reports and 2 case series. The review concludes that St John's Wort decreases cyclosporine blood levels, potentially leading to transplant rejection.
St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.
Systematic review identifying clinically significant interactions between St John's wort and various prescribed medicines, including warfarin, cyclosporin, and oral contraceptives. These interactions are likely due to the induction of cytochrome P450 isoenzymes and P-glycoprotein by constituents in St John's wort, leading to decreased drug concentrations or effects.
A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review.
Systematic review and meta-analysis of 22 RCTs on St John's wort for depression. St John's wort was significantly more effective than placebo and had similar effectiveness to standard antidepressants, with fewer adverse effects.
Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.
RCT comparing the efficacy and tolerability of St John's wort extract (Hypericum perforatum) with imipramine in 324 outpatients with mild to moderate depression. Both treatments showed similar reductions in depression scores, but St John's wort had better tolerability and fewer adverse events.
St John's wort for depression: a systematic review.
Systematic review of randomized, controlled, double-blind trials assessing the efficacy, safety, and availability of St John's wort for depression. Found that St John's wort is more effective than placebo for mild to moderate depression, with low rates of side effects. More data needed for severe depression and comparison with other antidepressants.
The Effects of St. John's Wort on Healing of Stages 1 and 2 Pressure Injuries: A Randomized Controlled Trial.
RCT evaluating the effects of topical St. John's wort oil on wound healing in Stages 1 and 2 pressure injuries in a nursing home setting. No significant differences in wound healing outcomes were found between the intervention and control groups.
Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's Wort.
Randomized crossover trial with 18 healthy volunteers comparing the effect of St. John's Wort on the pharmacokinetics of immediate-release and prolonged-release tacrolimus. St. John's Wort decreased exposure and maximum concentration of both tacrolimus formulations, with no statistical difference between them. The interaction was less pronounced in individuals with higher baseline CYP3A4 activity.
Herbal Infusions as a Part of the Mediterranean Diet and Their Association with Psychological Resilience: The Paradigm of Greek Mountain Tea
Cross-sectional study of 398 healthy adults in Greece exploring the relationship between herbal infusions and the Mediterranean Diet, and their association with psychological resilience. Greek mountain tea, St John's wort, and green tea were associated with higher levels of psychological resilience.
A Randomized Split-Face Study of Photodynamic Therapy With St. John's Wort and Indole-3-Acetic Acid for the Treatment of Acne.
A randomized split-face study comparing the efficacy and safety of St. John's Wort-photodynamic therapy (PDT) with indole-3-acetic acid-PDT for acne treatment. SJW-PDT significantly reduced acne lesion counts, sebum secretion, erythema index, roughness, and wrinkles, showing it as a safe and effective treatment option for acne and skin rejuvenation.
Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial.
Randomized clinical trial evaluating the effects of St. John's wort on intravenous fentanyl pharmacokinetics, pharmacodynamics, and clinical effects in healthy volunteers. St. John's wort did not alter fentanyl pharmacokinetics, pharmacodynamics, or clinical effects, suggesting no effect on hepatic clearance or blood-brain barrier efflux.
Antidepressants for smoking cessation.
Meta-analysis assessing the effect and safety of antidepressant medications, including St. John's Wort, for smoking cessation. The analysis found no significant effect of St. John's Wort on smoking cessation.
A randomized clinical trial of St. John's wort for smoking cessation.
Randomized, blinded, placebo-controlled trial of St. John's Wort (SJW) for smoking cessation in 118 subjects. No significant differences in abstinence rates were observed between SJW dose groups and placebo. SJW did not attenuate withdrawal symptoms, and no significant side-effects were noted.
Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial.
A double-blind, randomized, placebo-controlled trial evaluated the effectiveness of a combination of Hypericum perforatum (St. John's wort) and Vitex agnus-castus in managing menopausal symptoms in 100 women. The study found no significant differences between the herbal combination and placebo for hot flush episodes or other endpoints. Both groups showed improvements, but the herbal combination was not superior to placebo.
A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome.
A randomized, double-blind, placebo-controlled trial evaluated the efficacy of St John's Wort (SJW) in treating irritable bowel syndrome (IBS) over 12 weeks. The study found that SJW was less effective than placebo in improving bowel symptom scores and other IBS-related outcomes.
Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.
Randomized, double-blind, placebo-controlled trial of 54 children with ADHD testing 300 mg of St. John's Wort (Hypericum perforatum) standardized to 0.3% hypericin. No significant improvement in ADHD symptoms was observed compared to placebo over 8 weeks.
The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study.
Double-blind placebo-controlled study of St. John's Wort (Hypericum) in 150 patients with minor depressive symptoms or dysthymia. The study found significant improvement in mood for non-dysthymic patients treated with Hypericum, as measured by BDI and VAS, though HAM-D showed only a tendency towards significance.
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
This double-blind, randomized trial compared the antidepressant efficacy and safety of St John's wort, fluoxetine, and placebo in patients with major depressive disorder. St John's wort showed significantly lower mean HAMD-17 scores compared to fluoxetine and a trend towards superiority over placebo, with higher remission rates. It was safe and well tolerated.
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Two randomized, placebo-controlled studies evaluated the pharmacokinetic interaction between a low-hyperforin St John's wort extract and alprazolam, caffeine, tolbutamide, and digoxin in 56 healthy volunteers. No statistically significant differences were found in the primary kinetic parameters between the placebo and SJW groups, suggesting clinically irrelevant interactions with the low-hyperforin SJW extract.
Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial.
RCT of 184 outpatients with somatoform disorders comparing 600 mg daily of St. John's Wort extract LI 160 to placebo for 6 weeks. St. John's Wort showed statistically significant superiority over placebo in efficacy measures, with 45.4% of patients classified as responders compared to 20.9% with placebo. Tolerability was equivalent to placebo.
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin.
A randomized, placebo-controlled study in 96 healthy volunteers evaluated the pharmacokinetic interaction of various St John's wort formulations and doses with digoxin. High-dose hyperforin-rich extracts significantly reduced digoxin's pharmacokinetic parameters, while other formulations showed no significant interaction.
Treating depression comorbid with anxiety--results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses.
Open, practice-oriented study evaluating high-dose combination therapy of St John's wort and valerian extract for depression comorbid with anxiety. The combination therapy improved anxiety symptoms more quickly than St John's wort monotherapy and was well tolerated.
St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial.
This multicentre, randomised, placebo-controlled trial studied the efficacy of St John's wort extract (LI 160) in 151 out-patients with somatoform disorders. The extract showed superior efficacy in reducing somatic anxiety as measured by the Hamilton Anxiety Scale compared to placebo, with excellent tolerability.
St John's wort or sertraline? Randomized controlled trial in primary care.
Double-blind, randomized 12-week trial comparing St John's wort (SJW) and sertraline in 87 primary care patients with major depression. No significant differences in depression scores were found between the groups, but SJW had fewer side effects, suggesting it as a good first choice for this population.
Effect of St John's wort on the pharmacokinetics of fexofenadine.
A 3-period, open-label study examined the effect of St John's wort on the pharmacokinetics of fexofenadine. A single dose of St John's wort increased the maximum plasma concentration of fexofenadine by 45% and decreased oral clearance by 20%. Long-term administration reversed these effects, decreasing maximum plasma concentration by 35% and increasing oral clearance by 47%.
St. John's wort has no effect on pain in polyneuropathy.
Randomized, double-blind, placebo-controlled cross-over study testing St. John's wort for pain relief in polyneuropathy. Fifty-four patients participated, with no significant effect on pain compared to placebo.
Indinavir concentrations and St John's wort.
RCT showing that St John's Wort reduced the area under the curve of the HIV-1 protease inhibitor indinavir by a mean of 57% and decreased the extrapolated 8-hour indinavir trough by 81% in healthy volunteers. This reduction in indinavir exposure could lead to drug resistance and treatment failure.
St. John's wort for depression: a meta-analysis of well-defined clinical trials.
Meta-analysis of well-defined clinical trials assessing St. John's wort (Hypericum perforatum) for depression. Hypericum was 1.5 times more likely to result in an antidepressant response than placebo and was equivalent to tricyclic antidepressants. The meta-analysis also showed a higher dropout rate and more severe side effects in the TCA group. Design problems in existing studies prevent definitive conclusions about its effectiveness.
Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.).
Systematic review of adverse drug reactions associated with St. John's wort for treating mild to moderate depression. The herb is generally well tolerated, with adverse reactions similar to placebo. Common effects include gastrointestinal symptoms, dizziness, and tiredness, with rare cases of photosensitivity.
St John's Wort (Hypericum perforatum)--a herbal antidepressant.
Meta-analysis of clinical studies indicating that St John's wort (Hypericum perforatum) has antidepressant effects, with a response rate of 60-70% in mild and moderate depression. The preparations are well tolerated with rare adverse reactions, making them suitable for outpatient practice.
Polyphenol and Flavonoid Content and Antioxidant Activity of Hypericum perforatum L. (St. John’s Wort) Extracts for Potential Pharmaceutical and Cosmetic Applications
The study assessed the antioxidant activity and polyphenolic content of two commercial St. John's Wort extracts used in cosmetics. The extracts demonstrated free radical-scavenging properties, indicating potential for cellular protection against oxidative stress.
Determination of the contents of bioactive compounds in St. John’s wort (Hypericum perforatum): Comparison of commercial and wild samples
The study analyzed the content of flavonoids and antioxidant activity in commercial and wild-grown St. John's Wort samples using LC–MS/MS. It evaluated functional constituents like phenolic acids, quercetin, rutin, pseudohypericin, and hypericin. Wild plants showed higher amounts of compounds with antidepressant effects than commercially grown plants.
Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans
The study investigates the influence of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban, focusing on its role as a cytochrome P450 CYP3A4 and P-glycoprotein (P-gp) inducer.
Optimization of Light Intensity, Temperature, and Nutrients to Enhance the Bioactive Content of Hyperforin and Rutin in St. John’s Wort
The study used design of experiments and response surface methodology to optimize light intensity, temperature, and nutrient conditions for enhancing hyperforin and rutin content in St. John's wort. Hyperforin and rutin contents were significantly influenced by temperature and light intensity, while nutrient solution concentration had little effect. The study provides optimal conditions for bioactive compound accumulation in St. John's wort.
Subchronic treatment with St John's wort produces a positive shift in emotional processing in healthy volunteers.
RCT with 48 healthy participants given St John's wort or placebo for seven days. St John's wort treatment produced positive shifts in emotional processing, similar to other antidepressants, by reducing recognition of disgusted faces and increasing memory for positive words.
Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
Phase I clinical trial with 12 healthy volunteers assessing the interaction of macitentan and rivaroxaban, and the effect of St John's Wort on their pharmacokinetics. St John's Wort significantly increased CYP3A activity and reduced exposure to rivaroxaban and macitentan, suggesting the combination of St John's Wort with rivaroxaban should be avoided.
Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone.
Open cross-over study in 20 healthy male subjects examining the interaction between St John's wort and metformin. St John's wort decreased the renal clearance of metformin and improved glucose tolerance by enhancing insulin secretion.
St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactions.
Phase I trial assessing dose-dependent metabolic effects of St. John's wort co-administered with rifampicin in 12 healthy volunteers. Five of six female participants developed ambient temperature-dependent allodynia and paresthesia in sun-exposed areas, with symptoms persisting and leading to phototoxic erythrodermia. These adverse effects were not observed in male participants.
The effect of St John's wort on the pharmacokinetics of docetaxel.
RCT investigating the pharmacokinetic interaction between St John's Wort (SJW) and docetaxel in 10 cancer patients. SJW supplementation significantly decreased the mean area under the docetaxel plasma concentration-time curve and increased docetaxel clearance, suggesting potential undertreatment of cancer patients when used concomitantly.
Evaluation of Pharmaceutical Products of St. John’s Wort Efficacy Added on Tricyclic Antidepressants in treating Major Depressive Disorder: A Double Blind Randomized Control Trial
Double blind randomized controlled trial evaluating the efficacy of St. John's Wort (Hypericum perforatum) added to tricyclic antidepressants in treating major depressive disorder. The study included 40 patients and found significant improvement in depression, sleep quality, and energy levels in the St. John's Wort group compared to placebo.
St John's wort greatly decreases the plasma concentrations of oral S-ketamine.
Randomized cross-over study with 12 healthy subjects to investigate the effect of St John's wort on the pharmacokinetics and pharmacodynamics of oral S-ketamine. St John's wort significantly decreased the plasma concentrations of ketamine and its major metabolite norketamine, suggesting a potential interaction that could render usual doses of S-ketamine ineffective.
St John's wort greatly reduces the concentrations of oral oxycodone.
Placebo-controlled, randomized, cross-over study with 12 healthy participants assessing the effect of St John's wort on oxycodone metabolism. St John's wort administration reduced oxycodone plasma concentrations by 50% and decreased its elimination half-life. The self-reported drug effect of oxycodone decreased significantly, indicating a potential drug-supplement interaction.
St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial.
RCT of 28 adults with major depressive disorder and comorbid anxiety testing St. John's Wort and Kava against placebo. The combination showed a significant reduction in depression scores in the first phase but no significant effects on anxiety or quality of life.
St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive
RCT investigating the effects of St John's wort extract (Ze 117) on the pharmacokinetics of ethinylestradiol and 3-ketodesogestrel in 16 healthy female volunteers. The study found that Ze 117 does not significantly alter the pharmacokinetics of the hormonal components of a low-dose oral contraceptive.
Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis.
A double-blind, randomized, placebo-controlled trial evaluated the effectiveness of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women. The herbal combination was superior to placebo for total PMS-like scores and specific subclusters, suggesting potential clinical application for managing PMS-like symptoms.
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
RCT assessing the interaction between St. John's wort (Movina) and atorvastatin in 16 patients with hypercholesterolemia. St. John's wort significantly increased LDL and total cholesterol levels compared to control, indicating a negative interaction with atorvastatin.
Lack of pharmacokinetic interaction between St. John's wort and prednisone.
This study examined the effects of long-term St. John's Wort administration on the pharmacokinetics of prednisone and prednisolone in eight male subjects. After 28 days of SJW treatment, there were no significant alterations in the pharmacokinetic parameters for prednisone or prednisolone.
Effects of St. John's wort supplementation on ibuprofen pharmacokinetics.
RCT examining the effect of 3 weeks of St. John's wort administration on the pharmacokinetics of ibuprofen in 8 male subjects. St. John's wort had no significant effects on the C(max) and AUC of either ibuprofen stereoisomer, though it reduced the mean residence time of S(+)-ibuprofen by 31%. No ibuprofen dose adjustments are necessary when co-administered with St. John's wort.
Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach.
This study investigated herb-drug interactions with warfarin in 24 healthy subjects using a population pharmacokinetic-pharmacodynamic modeling approach. St John's wort significantly increased S-warfarin clearance, while Asian ginseng produced a moderate increase. Ginkgo and ginger did not affect warfarin pharmacokinetics. None of the herbs had a direct effect on warfarin pharmacodynamics.
A Phase II study of St. John's Wort for smoking cessation.
Phase II study examining the feasibility and efficacy of St. John's Wort for smoking cessation. Among 24 evaluable subjects, the 12-week quit rate was 37.5%. SJW was generally well tolerated and may be effective in maintaining smoking cessation.
Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers.
RCT of 20 healthy male volunteers given low or high doses of Jarsin (St John's Wort extract) for 7 days. Low dose increased salivary cortisol, while high dose had no effect. Melatonin levels were unaffected by either dose.
St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study.
Pilot RCT of 40 subjects with social anxiety disorder comparing 12 weeks of St. John's Wort to placebo. No significant difference was found between the groups on the Liebowitz Social Anxiety Scale, suggesting no efficacy of SJW in social phobia.
Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba.
RCT assessing the effects of St John's wort, garlic oil, Panax ginseng, and Ginkgo biloba on cytochrome P450 activity in elderly subjects. St John's wort significantly induced CYP3A4 and CYP2E1 activity, while garlic oil inhibited CYP2E1. P. ginseng showed a statistically significant but clinically irrelevant inhibition of CYP2D6. No effects on CYP1A2 activity were observed.
Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans.
Double-blind, randomized, placebo-controlled, crossover study with 16 healthy subjects examining the effects of St John's wort on catecholamine turnover and cardiovascular regulation. St John's wort had no effect on blood pressure, heart rate, or norepinephrine levels, but increased plasma DOPAC concentrations, suggesting a potential novel mode of action.
Drug interaction between St John's Wort and quazepam.
RCT examining the interaction between St John's Wort (SJW) and quazepam in 13 healthy subjects. SJW decreased plasma quazepam concentrations by enhancing CYP3A4 activity but did not influence the pharmacodynamic effects of quazepam.